COSCIENS Biopharma (TSE:CSCI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
COSCIENS Biopharma Inc. has announced the appointment of Pierre Labbé as a new director and the Chair of the Audit Committee, succeeding Dennis Turpin who resigned. Labbé, with over 30 years in financial leadership, including roles at Fonds QScale S.E.C. and IMV Inc., brings vast experience in finance, M&A, and strategic planning to COSCIENS, a company known for developing a broad range of pharmaceutical and cosmeceutical products.
For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.